G-protein-coupled receptor heterodimerization: Assay technologies to clinical significance

Current Opinion in Drug Discovery and Development

Volumn 10, Issue 5, 2007, Pages 580-589

  Kent, T ^a   McAlpine, C ^a   Sabetnia, S ^a   Presland, J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Dimerization; Drug discovery; G protein coupled receptor; Oligomerization

Indexed keywords

3,6' GUANIDINONALTRINDOLE; CAPTOPRIL; CLOPIDOGREL; G PROTEIN COUPLED RECEPTOR; INDOLE DERIVATIVE; LEVODOPA; OLIGOMER; SUMATRIPTAN SUCCINATE; UNCLASSIFIED DRUG;

BINDING SITE; BIOLUMINESCENCE RESONANCE ENERGY TRANSFER; DIMERIZATION; DRUG DETERMINATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ENDOPLASMIC RETICULUM; FLUORESCENCE RESONANCE ENERGY TRANSFER; GOLGI COMPLEX; HUMAN; HYPERTENSION; IMMUNOHISTOCHEMISTRY; INTERNALIZATION; LIGAND BINDING; MIGRAINE; OLIGOMERIZATION; PARKINSON DISEASE; PROTEIN DETERMINATION; REVIEW;

ANIMALS; BINDING SITES; DIMERIZATION; DRUG DESIGN; HUMANS; LIGANDS; MOLECULAR STRUCTURE; PROTEIN BINDING; PROTEIN TRANSPORT; RECEPTORS, G-PROTEIN-COUPLED; TECHNOLOGY, PHARMACEUTICAL;

EID: 34548421579     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Milligan G, Ramsay D, Pascal G, Carrillo JJ: GPCR dimerization. Life Sci (2003) 74(2-3):181-188.
2. B receptors - the first 7TM heterodimers. Trends Pharmacol Sci (1999) 20(10):396-399.
3. Bulenger S, Marullo S, Bouvier M: Emerging role of homo- and heterodimerization in G-protein-coupled receptor biosynthesis and maturation. Trends Pharmacol Sci (2005) 26(3):131-137.
4. 1 bradykinin receptor homo-oligomers in receptor cell surface expression and signaling: Effects of receptor fragments. Mol Pharmacol (2005) 67(1):309-318.
5. Law PY, Erickson-Herbrandson LJ, Zha QQ, Solberg J, Chu J, Sarre A, Loh HH: Heterodimerization of μ- and δ-opioid receptors occurs at the cell surface only and requires receptor-G protein interactions. J Biol Chem (2005) 280(12):11152-11164.
6. Jordan BA, Devi LA: G-protein-coupled receptor heterodimerization modulates receptor function. Nature (1999) 399(6737):697-700.
7. Leung PK, Chow KB, Lau PN, Chu KM, Chan CB, Cheng CH, Wise H: The truncated ghrelin receptor polypeptide (GHS-R1b) acts as a dominant-negative mutant of the ghrelin receptor. Cell Signal (2007) 19(5):1011-1022.
8. 1 antagonist, SR141716. J Biol Chem (2003) 278(26):23731-23737.
9. 1 cannabinoid receptor interactions: Reciprocal inhibition of receptor signaling and neuritogenesis. Br J Pharmacol (2006) 148(4):387-395.
10. 2 heterodimers are present in striatum, require concurrent activation of both receptors for signaling and can be identified by their unique pharmacology.
11. McLaughlin JN, Patterson MM, Malik AB: Protease-activated receptor-3 (PAR3) regulates PAR1 signaling by receptor dimerization. Proc Natl Acad Sci USA (2007) 104(13):5662-5667. • Describes a study in which the non-signaling receptor PAR3 was shown to heterodimerize with PAR1, thereby modulating G protein selectivity and PAR1-mediated endothelial permeability.
12. Vassilatis DK, Hohmann JG, Zeng H, Li F, Ranchalis JE, Mortrud MT, Brown A, Rodriguez SS, Weller JR, Wright AC, Bergmann JE, Gaitanaris GA: The G protein-coupled receptor repertoires of human and mouse. Proc Natl Acad Sci USA (2003) 100(8):4903-4908.
13. Hakak Y, Shrestha D, Goegel MC, Behan DP, Chalmers DT: Global analysis of G-protein-coupled receptor signaling in human tissues. FEBS Lett (2003) 550(1-3):11-17.
14. Daly CJ, McGrath JC: Fluorescent ligands, antibodies, and proteins for the study of receptors. Pharmacol Ther (2003) 100(2):101-118.
15. Harrison C, van der Graaf PH: Current methods used to investigate G protein coupled receptor oligomerization. J Pharmacol Toxicol Methods (2006) 54(1):26-35.
16. 2 receptor dimer formation: Evidence from ligand binding. J Biol Chem (2001) 276(25):22621-22629.
17. Park PS, Sum CS, Pawagi AB, Wells JW: Cooperativity and oligomeric status of cardiac muscarinic cholinergic receptors. Biochemistry (2002) 41 (17):5588-5604.
18. Cvejic S, Devi LA: Dimerization of the δ opioid receptor: Implication for a role in receptor internalization. J Biol Chem (1997) 272(43):26959-26964.
19. 2-adrenergic receptor transmembrane domain inhibits both receptor dimerization and activation. J Biol Chem (1996) 271(27):16384-16392.
20. Lee C, Ji I, Ryu K, Song Y, Conn PM, Ji TH: Two defective heterozygous luteinizing hormone receptors can rescue hormone action. J Biol Chem (2002) 277(18):15795-15800.
21. Carrillo JJ, Pediani J, Milligan G: Dimers of class A G-protein-coupled receptors function via agonist-mediated trans-activation of associated G proteins. J Biol Chem (2003) 278(43):42578-42587.
22. Pfleger KD, Eidne KA: Monitoring the formation of dynamic G-protein-coupled receptor-protein complexes in living cells. Biochem J (2005) 385(3):625-637.
23. Ayoub MA, Couturier C, Lucas-Meunier E, Angers S, Fossier P, Bouvier M, Jockers R: Monitoring of ligand-independent dimerization and ligand-induced conformational changes of melatonin receptors in living cells by bioluminescence resonance energy transfer. J Biol Chem (2002) 277(24):21522- 21528.
24. 2-adrenergic receptor homo- and heterodimerization by bioluminescence resonance energy transfer. J Biol Chem (2002) 277(47):44925-44931.
25. Lopez-Gimenez JF, Canals M, Pediani JD, Milligan G: The α1B-adrenoceptor exists as a higher-order oligomer: Effective oligomerization is required for receptor maturation, surface delivery, and function. Mol Pharmacol (2007) 71(4):1015-1029. • Describes the development of sequential three-color FRET as an extension of existing biophysical techniques, which permits the identification of GPCR oligomers rather than dimers.
26. 2-adrenergic receptors: A role in trafficking and mitogen-activated protein kinase activation. Proc Natl Acad Sci USA (2001) 98(1):343-348.
27. Milasta S, Pediani J, Appelbe S, Trim S, Wyatt M, Cox P, Fidock M, Milligan G: Interactions between the Mas-related receptors MrgD and MrgE alter signaling and trafficking of MrgD. Mol Pharmacol (2006) 69(2):479-491.
28. Cara Therapeutics Inc, Tarrytown, NY, USA. http://www. caratherapeutics.com
29. Dimerix Bioscience Pty Ltd, Nedlands, WA, Australia. www.dimerix.com
30. PatoBIOS Inc, Toronoto, ON, Canada. www.patobios.com
31. 2- adrenoceptor antibody behave as antagonists. Mol Pharmacol (2000) 58(2):373-379.
32. 1 receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness. Nat Med (2001) 7(9):1003-1009.
33. 1 heterodimerization to the pathogenic events that lead to atherosclerotic lesion formation and demonstrate how dimerization may be used as a biomarker for successful drug treatment.
34. 1B agonist. Bioorg Med Chem Lett (1998) 8(6):675-680.
35. Messer WS Jr: Bivalent ligands for G protein-coupled receptors. Curr Pharm Des (2004) 10(17):2015-2020.
36. 2 phenotypes. Selective targeting of δ-κ heterodimers. J Med Chem (2004) 47(12):2969-2972.
37. Waldhoer M, Fong J, Jones RM, Lunzer MM, Sharma SK, Kostenis E, Portoghese PS, Whistler JL: A heterodimer-selective agonist shows in vivo relevance of G-protein-coupled receptor dimers. Proc Natl Acad Sci USA (2005) 102(25):9050-9055. •• A heterodimer-specific agonist was used to demonstrate the functional relevance of δ/κ-opioid receptor heterodimers in a physiological context.
38. 1 melatonin receptor function through heterodimerization. EMBO J (2006) 25(13):3012-3023.
39. 2-adrenergic receptor subtypes optimizes β-adrenergic modulation of cardiac contractility. Circ Res (2005) 97(3):244-251.
40. 12 receptors present in platelets, thereby disrupting homo-oligomeric complexes and receptor function.
41. Schwartz TW, Holst B: Ago-allosteric modulation and other types of allostery in dimeric 7TM receptors. J Recept Signal Transduct Res (2006) 26(1-2):107-128.
42. 2 heteromeric receptor complexes and their function. J Mol Neurosci (2005) 26(2-3):209-220.
43. He L, Whistler JL: An opiate cocktail that reduces morphine tolerance and dependence. Curr Biol (2005) 15(11):1028-1033.
44. Barki-Harrington L, Luttrell LM, Rockman HA: Dual inhibition of β-adrenergic and angiotensin II receptors by a single antagonist: A functional role for receptor-receptor interaction in vivo. Circulation (2003) 108(13):1611-1618.
45. 2-adrenergic receptors within a unique heterodimeric complex. J Clin Invest (2006) 116(5):1400-1409. • Illustrates how heterodimerization may generate a novel form of receptor cross-talk and result in unexpected drug interactions.
46. Mellado M, Rodríguez-Frade JM, Vila-Coro AJ, de Ana AM, Martínez-A C: Chemokine control of HIV-1 infection. Nature (1999) 400(6746):723-724.
47. Rodríguez-Frade JM, del Real G, Serrano A, Hernanz-Falcón P, Soriano SF, Vila-Coro AJ, de Ana AM, Lucas P, Prieto I, Martínez-A C, Mellado M: Blocking HIV-1 infection via CCR5 and CXCR4 receptors by acting in trans on the CCR2 chemokine receptor. EMBO J (2004) 23(1):66-76.